In this webinar, genomics scientists detail how advances in immuno-oncology resulting from next-generation sequencing (NGS) are helping researchers better stratify patients for clinical trials. They are utilizing DNA and RNA sequencing to identify individual and combinatorial biomarkers, which enable them to identify ideal participants and develop new therapeutic algorithms. Through this approach, immunotherapies may improve treatment response—and survival rates—beyond that of chemotherapy, radiation, and other targeted therapies. Webinar at a glance • Obtain an overview of therapeutic approaches to cancer including immune-based therapies. • Learn the biomarkers considered in developing immuno-oncology–based therapies. • Understand the value of companion and complementary diagnostics in immuno-oncology. • Explore the various genomic tools for categorizing tumor and host-predictive biomarkers. Presenters: Adrian Benjamin, PhD Manager, Field Market Development, Oncology and Cell Biology Anup Madan, PhD Senior Technical Director, Genomic Services, Covance A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM